Antimicrobial chemotherapy and lung microdialysis: A review

International Journal of Antimicrobial Agents

Volumn 36, Issue 6, 2010, Pages 491-500

  Dhanani, Jayesh ^a,b   Roberts, Jason A ^a,b   Chew, Michelle ^c   Lipman, Jeffrey ^a,b   Boots, Robert J ^a,b   Paterson, David L ^a,b   Fraser, John F ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Antibiotics; Infections; Pharmacodynamics; Pharmacokinetics; Pulmonary

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFPIROME; CEFPODOXIME; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACCURACY; ANALYTIC METHOD; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TISSUE LEVEL; HUMAN; INFORMATION RETRIEVAL; LOADING DRUG DOSE; LUNG PARENCHYMA; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT SAFETY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SHORT SURVEY; SYSTEMATIC REVIEW; TISSUE DISTRIBUTION;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; LUNG; MICRODIALYSIS; PNEUMONIA, BACTERIAL;

EID: 78249263514     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.08.013     Document Type: Short Survey

References (130)

1. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. N Engl J Med 1995, 333:1618-1624.
2. Vincent J.L., Bihari D.J., Suter P.M., Bruining H.A., White J., Nicolas-Chanoin M.H., et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995, 274:639-644.
3. Rello J., Torres A., Ricart M., Valles J., Gonzalez J., Artigas A., et al. Ventilator-associated pneumonia by Staphylococcus aureus, Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994, 150:1545-1549.
4. Meyer K.S., Urban C., Eagan J.A., Berger B.J., Rahal J.J. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993, 119:353-358.
5. Heffron R. Pneumonia, with special reference to pneumococcus lobar pneumonia. The biology of pneumococcus: the bacteriological, biochemical and immunological characters and activities of Diplococcus pneumoniae 1979, Harvard University Press, Cambridge, MA, p. 302-8.
6. Bullowa J. The reliability of sputum typing and its relation to serum therapy. JAMA 1935, 105:1512-1518.
7. Friedland I.R., McCracken G.H. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994, 331:377-382.
8. Joukhadar C., Derendorf H., Müller M. Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol 2001, 57:211-219.
9. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10. [quiz 11-2].
10. Drusano G.L., Craig W.A. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997, 9(Suppl. 3):38-44.
11. Schentag J.J. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with Gram-negative pneumonia. Scand J Infect Dis Suppl 1990, 74:218-234.
12. Hyatt J.M., McKinnon P.S., Zimmer G.S., Schentag J.J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995, 28:143-160.
13. Müller M., Haag O., Burgdorff T., Georgopoulos A., Weninger W., Jansen B., et al. Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob Agents Chemother 1996, 40:2703-2709.
14. Müller M., Rohde B., Kovar A., Georgopoulos A., Eichler H.G., Derendorf H. Relationship between serum and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis. J Clin Pharmacol 1997, 37:1108-1113.
15. Bertazzoni Minelli E., Benini A., Muner A., Bassi C., Abbas H., Pederzoli P. Pefloxacin penetration into human necrotic pancreatic tissue. J Antimicrob Chemother 1996, 38:237-243.
16. 18F]trovafloxacin in healthy human subjects studied with positron emission tomography. Antimicrob Agents Chemother 1998, 42:2048-2054.
17. 18F]fleroxacin in healthy human subjects studied by using positron emission tomography. Antimicrob Agents Chemother 1993, 37:2144-2152.
18. Jynge P., Skjetne T., Gribbestad I., Kleinbloesem C.H., Hoogkamer H.F., Antonsen O., et al. In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans. Clin Pharmacol Ther 1990, 48:481-489.
19. Müller M., Stass H., Brunner M., Moller J.G., Lackner E., Eichler H.G. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999, 43:2345-2349.
20. Wollmer P., Pride N.B., Rhodes C.G., Sanders A., Pike V.W., Palmer A.J., et al. Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of positron tomography. Lancet 1982, 2:1361-1364.
21. Fischman A.J., Alpert N.M., Babich J.W., Rubin R.H. The role of positron emission tomography in pharmacokinetic analysis. Drug Metab Rev 1997, 29:923-956.
22. Front D., Israel O., Iosilevsky G., Even-Sapir E., Frenkel A., Peleg H., et al. Human lung tumors: SPECT quantitation of differences in Co-57 bleomycin uptake. Radiology 1987, 165:129-133.
23. Merrikin D.J., Briant J., Rolinson G.N. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983, 11:233-238.
24. 19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev 2000, 41:55-74.
25. Davies M.I. A review of microdialysis sampling for pharmacokinetic applications. Anal Chim Acta 1999, 379:227-249.
26. Eichler H.G., Müller M. Drug distribution. The forgotten relative in clinical pharmacokinetics. Clin Pharmacokinet 1998, 34:95-99.
27. Elmquist W.F., Sawchuk R.J. Application of microdialysis in pharmacokinetic studies. Pharm Res 1997, 14:267-288.
28. Fettweis G., Borlak J. Topics in xenobiochemistry-application of microdialysis techniques in pharmacokinetic studies. Xenobiotica 1996, 26:473-485.
29. Müller M. Microdialysis in clinical drug delivery studies. Adv Drug Deliv Rev 2000, 45:255-269.
30. Müller M. Tissue pharmacokinetics during early clinical drug development. Appl Clin Trials 1999, 8:56-60.
31. Ryan D.M. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother 1993, 31(Suppl. D):1-16.
32. Bergogne-Berezin E., Morel C., Benard Y., Berthelot G., Kafe H. Pharmacokinetic study of β-lactam antibiotics in bronchial secretions. Scand J Infect Dis Suppl 1978, 14:267-272.
33. Brunner M., Pernerstorfer T., Mayer B.X., Eichler H.G., Müller M. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 2000, 28:1754-1759.
34. Elliott A.M., Berning S.E., Iseman M.D., Peloquin C.A. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tuber Lung Dis 1995, 76:463-467.
35. Joukhadar C., Frossard M., Mayer B.X., Brunner M., Klein N., Siostrzonek P., et al. Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001, 29:385-391.
36. Lambert H.P. Clinical significance of tissue penetration of antibiotics in the respiratory tract. Scand J Infect Dis Suppl 1978, 14:262-266.
37. Kunin C.M., Craig W.A., Kornguth M., Monson R. Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci 1973, 226:214-224.
38. US Food and Drug Administration. Guidance for industry. Developing antimicrobial drugs-general considerations for clinical trials. Rockville, MD: FDA; 1998.
39. European Agency for the Evaluation of Medicinal Products. Evaluation of medicines for human use. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. London, UK: EMEA; 2000. CPMP/EWP/2655/99. [accessed 14 September 2010]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003420.pdf.
40. Baldwin D.R., Honeybourne D., Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992, 36:1176-1180.
41. Bergogne-Berezin E. New concepts in the pulmonary disposition of antibiotics. Pulm Pharmacol 1995, 8:65-81.
42. Zeitlinger M., Müller M., Joukhadar C. Lung microdialysis-a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS J 2005, 7:E600-E608.
43. Cole D.R., Pung J. Penetration of cefazolin into pleural fluid. Antimicrob Agents Chemother 1977, 11:1033-1035.
44. Kiss I.J., Faragó E., Pintér J. Serum and lung tissue levels of cephradine in thoracic surgery. Br J Clin Pharmacol 1976, 3:891-895.
45. Kroening U., Liebig S., Wundschock M. Tobramycin concentration in human lung tissue (author's transl). Infection 1978, 6:231-235. [in German].
46. Pennington J.E. Penetration of antibiotics into respiratory secretions. Rev Infect Dis 1981, 3:67-73.
47. Baldwin D.R., Maxwell S.R., Honeybourne D., Andrews J.M., Ashby J.P., Wise R. The penetration of cefpirome into the potential sites of pulmonary infection. J Antimicrob Chemother 1991, 28:79-86.
48. Baldwin D.R., Wise R., Andrews J.M., Ashby J.P., Honeybourne D. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990, 3:886-890.
49. Chastre J., Brun P., Fourtillan J.B., Soler P., Basset G., Manuel C., et al. Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibiotic. Antimicrob Agents Chemother 1987, 31:1312-1316.
50. Rebuck A.S., Braude A.C. Assessment of drug disposition in the lung. Drugs 1984, 28:544-553.
51. Honeybourne D., Andrews J.M., Ashby J.P., Lodwick R., Wise R. Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax 1988, 43:715-719.
52. Le Conte P., Potel G., Peltier P., Horeau D., Caillon J., Juvin M.E., et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993, 147:1279-1282.
53. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1990;141:S169-202.
54. Hand W.L., King-Thompson N.L., Steinberg T.H. Interactions of antibiotics and phagocytes. J Antimicrob Chemother 1983, 12(Suppl. C):1-11.
55. Harf R., Panteix G., Desnottes J.F., Diallo N., Leclercq M. Spiramycin uptake by alveolar macrophages. J Antimicrob Chemother 1988, 22(Suppl. B):135-140.
56. Barza M., Cuchural G. General principles of antibiotic tissue penetration. J Antimicrob Chemother 1985, 15(Suppl. A):59-75.
57. Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?. Curr Opin Pharmacol 2007, 7:498-504.
58. Marlin G.E., Burgess K.R., Burgoyne J., Funnell G.R., Guinness M.D. Penetration of piperacillin into bronchial mucosa and sputum. Thorax 1981, 36:774-780.
59. Decre D., Bergogne-Berezin E. Pharmacokinetics of quinolones with special reference to the respiratory tree. J Antimicrob Chemother 1993, 31:331-343.
60. Gail D.B., Lenfant C.J. Cells of the lung: biology and clinical implications. Am Rev Respir Dis 1983, 127:366-387.
61. Eisenberg E.J., Conzentino P., Eickhoff W.M., Cundy K.C. Pharmacokinetic measurement of drugs in lung epithelial lining fluid by microdialysis: aminoglycoside antibiotics in rat bronchi. J Pharmacol Toxicol Methods 1993, 29:93-98.
62. Tomaselli F., Maier A., Matzi V., Smolle-Juttner F.M., Dittrich P. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother 2004, 48:2228-2232.
63. Tyvold S.S., Solligard E., Lyng O., Steinshamn S.L., Gunnes S., Aadahl P. Continuous monitoring of the bronchial epithelial lining fluid by microdialysis. Respir Res 2007, 8:78.
64. Byl B., Jacobs F., Roucloux I., de Franquen P., Cappello M., Thys J.P. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Antimicrob Agents Chemother 1999, 43:681-682.
65. Cutillo A.G., Morris A.H., Ailion D.C., Durney C.H. Clinical implications of nuclear magnetic resonance lung research. Chest 1989, 96:643-652.
66. Shioya S., Haida M., Fukuzaki M., Kurita D., Tsuji C., Ohta Y., et al. Nuclear magnetic resonance study of lung water compartments in the rat. Am J Physiol 1997, 272:L772-L778.
67. Kipnis E., Guery B., Wiener-Kronish J. Promises and limitations of the bronchoscopic microsampling probe. Chest 2007, 132:1414.
68. Kikuchi E., Kikuchi J., Nasuhara Y., Oizumi S., Ishizaka A., Nishimura M. Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions. Antimicrob Agents Chemother 2009, 53:2799-2803.
69. Tomaselli F., Dittrich P., Maier A., Woltsche M., Matzi V., Pinter J., et al. Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis. Br J Clin Pharmacol 2003, 55:620-624.
70. de la Peña A., Liu P., Derendorf H. Microdialysis in peripheral tissues. Adv Drug Deliv Rev 2000, 45:189-216.
71. Ungerstedt U. Microdialysis-principles and applications for studies in animals and man. J Intern Med 1991, 230:365-373.
72. Lönnroth P., Jansson P.A., Smith U. A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol 1987, 253:E228-E231.
73. Stenken J.A. Methods and issues in microdialysis calibration. Anal Chim Acta 1999, 379:337-358.
74. Plock N., Kloft C. Microdialysis-theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci 2005, 25:1-24.
75. Stahle L., Segersvard S., Ungerstedt U. Drug distribution studies with microdialysis. II. Caffeine and theophylline in blood, brain and other tissues in rats. Life Sci 1991, 49:1843-1852.
76. Wang Y., Wong S.L., Sawchuk R.J. Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus. Pharm Res 1993, 10:1411-1419.
77. Arner P., Bolinder J., Eliasson A., Lundin A., Ungerstedt U. Microdialysis of adipose tissue and blood for in vivo lipolysis studies. Am J Physiol 1988, 255:E737-E742.
78. Müller M., Schmid R., Georgopoulos A., Buxbaum A., Wasicek C., Eichler H.G. Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 1995, 57:371-380.
79. Hutschala D., Kinstner C., Skhirtladze K., Mayer-Helm B.X., Zeitlinger M., Wisser W., et al. The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. Intensive Care Med 2008, 34:1827-1834.
80. Kennedy M.J., Van Riji A. Effects of surgery on the pharmacokinetic parameters of drugs. Clin Pharmacokinet 1998, 35:293-312.
81. Joukhadar C., Müller M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 2005, 44:895-913.
82. Müller M., Brunner M., Hollenstein U., Joukhadar C., Schmid R., Minar E., et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother 1999, 43:2056-2058.
83. Neckel U., Joukhadar C., Frossard M., Jager D., Müller M., Mayer B.X. Simultaneous determination of levofloxacin and ciprofloxacin in microdialysates and plasma by high-performance liquid chromatography. Anal Chim Acta 2002, 463:199-206.
84. US Food and Drug Administration, Department of Health and Human Service. Guidance documents on developing antimicrobial drugs. Anti-infective Drugs Advisory Committee. Washington, DC: Miller Reporting Co.; 1989. p. 167-79.
85. Curry F.E. Determinants of capillary permeability: a review of mechanisms based on single capillary studies in the frog. Circ Res 1986, 59:367-380.
86. Michel C.C. Filtration coefficients and osmotic reflexion coefficients of the walls of single frog mesenteric capillaries. J Physiol 1980, 309:341-355.
87. Renkin E.M. Multiple pathways of capillary permeability. Circ Res 1977, 41:735-743.
88. Joukhadar C., Klein N., Mayer B.X., Kreischitz N., Delle-Karth G., Palkovits P., et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med 2002, 30:1478-1482.
89. Sauermann R., Delle-Karth G., Marsik C., Steiner I., Zeitlinger M., Mayer-Helm B.X., et al. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother 2005, 49:650-655.
90. Zeitlinger M.A., Dehghanyar P., Mayer B.X., Schenk B.S., Neckel U., Heinz G., et al. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob Agents Chemother 2003, 47:3548-3553.
91. Zeitlinger M.A., Marsik C., Georgopoulos A., Müller M., Heinz G., Joukhadar C. Target site bacterial killing of cefpirome and fosfomycin in critically ill patients. Int J Antimicrob Agents 2003, 21:562-567.
92. Karjagin J., Pahkla R., Karki T., Starkopf J. Distribution of metronidazole in muscle tissue of patients with septic shock and its efficacy against Bacteroides fragilis in vitro. J Antimicrob Chemother 2005, 55:341-346.
93. Tegeder I., Schmidtko A., Brautigam L., Kirschbaum A., Geisslinger G., Lotsch J. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002, 71:325-333.
94. Herkner H., Müller M.R., Kreischitz N., Mayer B.X., Frossard M., Joukhadar C., et al. Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am J Respir Crit Care Med 2002, 165:273-276.
95. Hutschala D., Skhirtladze K., Zuckermann A., Wisser W., Jaksch P., Mayer-Helm B.X., et al. In vivo measurement of levofloxacin penetration into lung tissue after cardiac surgery. Antimicrob Agents Chemother 2005, 49:5107-5111.
96. Müller-Serieys C., Bancal C., Dombret M.C., Soler P., Murciano G., Aubier M., et al. Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients. Antimicrob Agents Chemother 1992, 36:2099-2103.
97. Forsgren A., Bellahsene A. Antibiotic accumulation in human polymorphonuclear leucocytes and lymphocytes. Scand J Infect Dis Suppl 1985, 44:16-23.
98. Prokesch R.C., Hand W.L. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1982, 21:373-380.
99. Zeitlinger M., Graninger W., Joukhadar C. Pharmacokinetics of the macrolides azithromycin, clarithromycin and roxithromycin in plasma and tissue-are there significant differences?. Wien Klin Wochenschr 2004, 11-12a:18-24.
100. De La Peña A., Dalla Costa T., Talton J.D., Rehak E., Gross J., Thyroff-Friesinger U., et al. Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats. Pharm Res 2001, 18:1310-1314.
101. Liu P., Fuhrherr R., Webb A.I., Obermann B., Derendorf H. Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats. Eur J Pharm Sci 2005, 25:439-444.
102. Marchand S., Dahyot C., Lamarche I., Mimoz O., Couet W. Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of noninfected rats. Antimicrob Agents Chemother 2005, 49:2356-2361.
103. Dahyot C., Marchand S., Pessini G.L., Pariat C., Debaene B., Couet W., et al. Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of Acinetobacter baumannii-infected rats. Antimicrob Agents Chemother 2006, 50:2265-2267.
104. Tasso L., Bettoni C.C., Oliveira L.K., Dalla Costa T. Evaluation of gatifloxacin penetration into skeletal muscle and lung by microdialysis in rats. Int J Pharm 2008, 358:96-101.
105. Marchand S., Frasca D., Dahyot-Fizelier C., Breheret C., Mimoz O., Couet W. Lung microdialysis study of levofloxacin in rats following intravenous infusion at steady state. Antimicrob Agents Chemother 2008, 52:3074-3077.
106. Endter S., Becker U., Daum N., Huwer H., Lehr C.M., Gumbleton M., et al. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell Tissue Res 2007, 328:77-84.
107. Leslie E.M., Deeley R.G., Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005, 204:216-237.
108. Scheffer G.L., Pijnenborg A.C., Smit E.F., Müller M., Postma D.S., Timens W., et al. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002, 55:332-339.
109. Steimer A., Franke H., Haltner-Ukomado E., Laue M., Ehrhardt C., Lehr C.M. Monolayers of porcine alveolar epithelial cells in primary culture as an in vitro model for drug absorption studies. Eur J Pharm Biopharm 2007, 66:372-382.
110. Zeitlinger M.A., Traunmüller F., Abrahim A., Müller M.R., Erdogan Z., Müller M., et al. A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. Int J Antimicrob Agents 2007, 29:44-50.
111. Brodie B.B., Kurz H., Schanker L.S. The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther 1960, 130:20-25.
112. de Lange E.C., de Boer A.G., Breimer D.D. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 2000, 45:125-148.
113. Matos F.F., Rollema H., Basbaum A.I. Simultaneous measurement of extracellular morphine and serotonin in brain tissue and CSF by microdialysis in awake rats. J Neurochem 1992, 58:1773-1781.
114. Nicolaysen L.C., Pan H.T., Justice J.B. Extracellular cocaine and dopamine concentrations are linearly related in rat striatum. Brain Res 1988, 456:317-323.
115. Stain F., Barjavel M.J., Sandouk P., Plotkine M., Scherrmann J.M., Bhargava H.N. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-β-d-glucuronide in the rat. J Pharmacol Exp Ther 1995, 274:852-857.
116. Poulin P., Theil F.P. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 2000, 89:16-35.
117. Joukhadar C., Stass H., Müller-Zellenberg U., Lackner E., Kovar F., Minar E., et al. Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 2003, 47:3099-3103.
118. Jansson P.A., Smith U., Lonnroth P. Interstitial glycerol concentration measured by microdialysis in two subcutaneous regions in humans. Am J Physiol 1990, 258:E918-E922.
119. Lonnroth P., Jansson P.A., Fredholm B.B., Smith U. Microdialysis of intercellular adenosine concentration in subcutaneous tissue in humans. Am J Physiol 1989, 256:E250-E255.
120. Lonnroth P., Carlsten J., Johnson L., Smith U. Measurements by microdialysis of free tissue concentrations of propranolol. J Chromatogr 1991, 568:419-425.
121. Lonnroth P., Smith U. Microdialysis-a novel technique for clinical investigations. J Intern Med 1990, 227:295-300.
122. Elmquist W.F., Yang H. An in-vitro microdialysis study of the thermodynamics of cyclosporine A binding to components of human plasma. Curr Sep 1993, 12:54.
123. Buerger C., Joukhadar C., Müller M., Kloft C. Development of a liquid chromatography method for the determination of linezolid and its application to in vitro and human microdialysis samples. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 796:155-164.
124. Delacher S., Derendorf H., Hollenstein U., Brunner M., Joukhadar C., Hofmann S., et al. A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother 2000, 46:733-739.
125. Hollenstein U., Brunner M., Mayer B.X., Delacher S., Erovic B., Eichler H.G., et al. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers. Clin Pharmacol Ther 2000, 67:229-236.
126. Joukhadar C., Klein N., Dittrich P., Zeitlinger M., Geppert A., Skhirtladze K., et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 2003, 51:1247-1252.
127. Joukhadar C., Klein N., Frossard M., Minar E., Stass H., Lackner E., et al. Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. Clin Pharmacol Ther 2001, 70:532-539.
128. Brunner M., Hollenstein U., Delacher S., Jager D., Schmid R., Lackner E., et al. Distribution and antimicrobial activity of ciprofloxacin in human soft tissues. Antimicrob Agents Chemother 1999, 43:1307-1309.
129. de la Pena A., Grabe A., Rand K.H., Rehak E., Gross J., Thyroff-Friesinger U., et al. PK-PD modelling of the effect of cefaclor on four different bacterial strains. Int J Antimicrob Agents 2004, 23:218-225.
130. Liu P., Rand K.H., Obermann B., Derendorf H. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents 2005, 25:120-129.